Arkolith/Insider Trading/LGND/Form 4

Haas Jason

DirectorLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed Aug 14, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.1M
Net Open-Market Flow
-$2.1M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 12, 2026Option exercise(M)6K$51.56$316K11K
Aug 12, 2026Sell(S)7K$292.81$2.1M4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 12, 2026Option exercise(M)6K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000114) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for LIGAND PHARMACEUTICALS INC

Build

Ask your agent about LGND insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0002001011-26-000114"
Ask your agent
Use Arkolith to summarize insider buying and selling at LIGAND PHARMACEUTICALS INC
over the last 90 days and cite the filings.